
News Feed
Interview with CEO Jon Peacock […]
Interview with CEO John Hatsopoulos […]
PRECLINICAL DATA ON THE IL-4 RECEPTOR ANTAGONIST PRS-060 PRESENTED AT THE EUROPEAN RESPIRATORY SOCIETY CONFERENCE; MARY FITZGERALD, PH.D., TO LEAD PIERIS RESPIRATORY DRUG DEVELOPMENT PROGRAM […]
Interview with CTO Mike Pavia […]
Interview with CEO Dennis Becker […]
Interview with CEO Ruedi Suter and EVP Jeff LaPlante […]
Interview with CEO Andy Marsh […]
Code Rebel Corp. (NASDAQ: CDRB) […]
Tumor-targeting CD137/HER2 Bispecifics Exhibit Desired Drug-Like Properties and Tumor-Dependent T Cell Activation […]
Copyright © 2019 The Wall Street Analyst, LLC. All rights reserved. Website by MyWebsiteSpot.com